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JEREMIAH D. WILLIAMS 
Carbapenem-resistant Enterobacteriaceae Case Definition Change: A Comparative Study of the 
Georgia Emerging Infections Program, 2011-2015 and 2016 
(Under Direction of Dr. Ike Okosun) 
 
ABSTRACT 
 
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) infections, with limited 
treatment options, pose a significant public health challenge. In 2011, the CDC’s phenotypic 
CRE case definition was nonsusceptibility to ≥ 1 carbapenem and resistance to 3rd generation 
cephalosporins but changed January 2016 to resistance to any carbapenem (including 
ertapenem). This study seeks to determine if this change influenced significant differences in 
patient characteristics. 
 
Methods: CRE cases in Metro Atlanta, Georgia were collected from 2011-2016. Cumulative 
incidence per 100,000, odds ratios, and  ꭓ2  estimates were calculated to identify trends. A 
univariable analysis was conducted to examine risk factors. Adjusting for covariates, the final 
multivariable model included invasive infection as the outcome and the new definition as the 
predictor. 
 
Results: A total of 1,144 CRE cases were confirmed from 2011-2016 in Metro Altanta. CRE 
incidence rates for all culture sources decreased pre-and post-definition change from 9.4 to 1.6. 
Central venous catheters and ICU stay 7 days prior, had the strongest association with invasive 
CRE infections; pre-(OR 5.9, 95% CI 1.4-4.3) and post-(OR 11.2, 95% CI 4.9-25.6) definition 
change. In the final model, the new definition (OR 0.6, 95% CI 0.4-0.9) predicted invasive 
infection.  
 
Discussion: CRE cases, following the new CRE case definition, had a 40% lower odds of 
invasive infections than that of the former. The cause of this shift is unclear as more data on 
antibiotic resistance profiles is needed to assess the definition’s overall performance. However, 
the impact of the new definition on invasive CRE infections is measurable and warrants further 
analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
KEYWORDS: Carbapenem-resistance Enterobacteriaceae, antibiotic resistance, CRE risk factors, case 
definition. 
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1. INTRODUCTION  
 
Carbapenem-resistant Enterobacteriaceae, (CRE) have become a major public health 
issue across the globe (Tamma, Huang, Opene, & Simner, 2016). These gram-negative 
organisms are multidrug-resistant pathogens that cause severe infections and have been 
associated with high mortality rates (Guh et al., 2015). According to a 2013 Morbidity and 
Mortality Weekly Report (MMWR), CRE-related infections mortality rates can be as high as 
40% to 50% (Patel et al. 2008; Schwaber et al., 2011; Chitnis et al., 2012; Vital Signs: 
Carbapenem-resistant Enterobacteriaceae, 2013). CREs commonly occur in healthcare settings, 
such as hospitals and long-term care facilities (LTCFs)(Guh et al., 2015). A cause of challenging 
healthcare-associated infections such as bacteremia, and often hidden throughout the hospital 
environment, clinicians have fewer treatment options since the emergence of CREs (Guh et al., 
2015). In the United States, the percentage of healthcare-associated infections caused by 
carbapenemase-resistant Enterobacteriaceae rose from 1.2%  to 4.2%, 2001-2011 (Jacob et al., 
2013; Chea et al., 2015). During which, the Klebsiella species accounted for the greatest 
increase, approximately 10% (Jacob et al., 2013; Chea et al., 2015).  
Enterobactericeae are a large diverse family of gram-negative bacteria. Many of which 
are not pathogenic, however the Georgia Emerging Infections Program (Georgia EIP) tracks 
carbapenem resistance to Escherichia coli, Klebsiella spp., and Enterobacter spp through it’s 
Multi-site Gram-negative Surveillance Initiative (MuGSI) (CDC, 2015).  MuGSI operates under 
the direction of the Centers for Disease Control and Prevention’s (CDC) Healthcare-Associated 
Infections Community Interface (HAIC) (CDC, 2015).   
Clinical cultures for patients suspected of CRE may present colonization (i.e. presence of 
CRE bacteria on a body surface but no clinical evidence of an infection) as Georgia EIP’s 
surveillance is limited to urine and sterile sites (i.e. blood, bone, internal body sites, etc.) (CDC, 
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2015).  Likewise, there is constant pressure to refine the case definition used to identify CRE and 
carbapenemase-producers among CREs, as the carbapenemase enzyme has been recognized as a 
driving factor in the spread of CRE (Chea et al., 2015). 
In November 2011, the CDC developed it’s first surveillance definition for CRE: 
Enterobacteriaceae that are non-susceptible to one of the following carbapenems: doripenem, 
meropenem, or imipenem AND resistant to all of the following third- generation cephalosporin; 
ceftriaxone, cefotaxime, and ceftazidime (Chea et al., 2015). January 2016, the CDC modified its 
surveillance definition for CRE to align with other state reportable definitions and a recently 
released Council for State and Territorial Epidemiologist (CSTE) position statement (Chea et al., 
2015).  The new phenotypic case definition added ertapenem, changed the breakpoint for 
carbapenems to resistant, and dropped the cephalosporin requirement. Resistance to ertapenem 
was not required in the previous case definition as it was considered too sensitive and had a 
different breakpoint from the other carbapenems (Chea et al., 2015). However, growing 
ertapenem resistance among CREs made its inclusion in the new definition necessary (Chea et 
al., 2015). This new definition was projected to be more sensitive for detecting carbapenemase 
producers than the previous definition but also had lower specificity (Chea et al., 2015) 
 Though the case definition change was intended to more accurately identify more 
positive CRE cases, the effects of the case definition change on the CRE patient population are 
not well described. As such, a thorough evaluation of how this recent case definition change 
could provide guidance on how to continue improving CRE surveillance as well as provide 
valuable epidemiological data specific to the metropolitan Atlanta area.  
The aim of this analysis is to compare and describe the differences in CRE cases from 
2011-2015 study period (study period 1) and 2016 CRE study period (study period 2) in the 
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metropolitan Atlanta area. Specifically, the following hypothesis will be tested: If the current 
CDC CRE surveillance definition was designed to be more simple and sensitive, surveillance 
efforts in Atlanta should have an impact on patient profiles.  
This study will contribute to the Georgia EIP’s effort to conduct accurate CRE 
surveillance and will help provide a better understanding of the CRE patient population. Thus, 
study findings will also serve as a guide in designing prevention and control measures to combat 
the spread of CREs. Several questions will direct this study: 1) Was there a significant difference 
in CRE incidence rates between the two study periods? 2) Did the incidence rates differ between 
hospitals and long-term care facilities? 3) Were there differences between cases with positive 
urinary cultures and invasive infections regarding demographics, healthcare exposures, and 
device-associated infections 
2. LITERATURE REVIEW 
 
2.1 Carbapenem Use and Increasing Resistance 
 
Carbapenems were first developed in the 1980s and derived from thyanamycin (Perez, 
Rodrigues, & Dias, 2015). Imipenem and meropenem were the first of this drug class and are 
considered broad-spectrum antibiotics, placing them at the forefront in the fight against hard-to-
treat nosocomial infections. During this period, carbapenems were effective against the vast 
majority of Enterobacteriaceae (Papp-Wallace, Endimiani, Taracila, & Bonomo, 2011). 
By the 1990s, Enterobacteriaceae began showing resistance to cephalosporins, through 
developing an enzyme that disables these agents called extended-spectrum β-lactamase (Perez, 
Rodrigues, & Dias, 2015). Therefore, clinicians were forced to use carbapenems, which 
remained susceptible (Rahal, 1998). Both are β-lactam antibiotics (beta-lactam antibiotics) which 
is a class of broad-spectrum antibiotics, comprised of anti-microbial agents that have a β-lactam 
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ring in their molecular framework (Holten & Onusko, 2000). This class of antibiotics is further 
divided into several subgroups; cephalosporins (cephems), penicillin offshoots (penams), 
carbapenems, and monobactams (Holten & Onusko, 2000). Ertapenem, another carbapenem with 
an extended half-life and once-daily dosing, was introduced in 2001 (Perez, Rodrigues, & Dias, 
2015). Consequently, this carbapenem was a favorable option for treating community cases 
(Livermore, Sefton, & Scott, 2003). Launched in 2005, doripenem is the latest addition to the 
carbapenem class of antibiotics (Bazan, Martin, & Kaye, 2009).  
Similar to imipenem and meropenem, doripenem has broad-spectrum activity and is 
effective against Pseudomonas aeruginosa, prompting more use of carbapenems (Bazan, Martin, 
& Kaye, 2009). A study, involving 35 university hospitals in the United States, found that 
carbapenem use rose by 59% from 2002 to 2006 (Pakyz, MacDougall, Oinonen, & Polk, 2008).   
By the early 2000’s, carbapenem resistance in Enterobactiericeae was documented in 
North America and began spreading in the United States after a series of hospital-related 
outbreaks in the Northeast (Perez, Rodrigues, & Dias, 2015). This resistance was due, in part, to 
the development of another enzyme called carbapenemases. Carbapenemases are β-lactamases 
with the ability to hydrolyze cephalosporins,  monobactams, penicillins, and carbapenems 
(Queenan & Bush, 2007).  
2.2 Emergence of CRE and Mechanisms for Resistance 
 
Like other pathogens, CRE can be transmitted person-to-person. Yet, there are many 
multiple mechanisms that contribute to carbapenem resistance (Capone et al., 2013). One of 
which is via plasmids (Capone et al., 2013).  Plasmids are particularly predominant among 
Enterobacteriaceae and can reproduce irrespectively of chromosomal DNA (Carattoli, 2011; 
Schwaber, Carmeli, & Harbarth, 2011; Plasmid | microbiology, 2018). The resistance gene can 
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be implanted into plasmids of gram-negative bacteria and can transfer  resistance not only from 
patient to patient but also from ne species of bacteria to another species, resulting in more 
species becoming drug resistant (Capone et al., 2013).  
Carbapenemases are part of several molecular classes; A, B, and D β-lactamases (see 
Table 1) (Queenan & Bush, 2007 ).  
Table 1: Carbapenemases 
Classes Enzymes Most Common Bacteria 
Class A *KPC(1-10), SME, IMI, 
NMC, GES 
Enterobacteriaceae (seen rarely in P. 
aeruginosa) 
Class B  
(metallo-β-
lactamases) 
IMP, VIM, GIM, SPM, 
NDM-1 
P. aeruginosa, Enterobacteriaceae, 
Acinetobacter spp. 
Class D OXA Acinetobacter spp., P. aeruginosa and 
rare Enterobacteriaceae 
*Plasmid, [A] KPC-K. pneumoniae carbapenemase, SME- S. Marcesens enzyme, NMC-Not Metallo Carbapenemase, IMI-IM hydrolyzing β-lactamase, GES-Guiana extended 
spectrum; [B] VIM-Verona Integron Encoded MBL; NDM-1-New Delhi β-lactamase; [D] Oxacilin hydrolyzing. Enzyme Specific Activity Spectrum: KPC(1-10)- All β-lactams; 
SME, IMI, NMC -Carbapenem, Aztreonam but not 3rd & 4th generation Cephalosporins; GES-Imipenem and 3rd / 4th generation; IMP, VIM, GIM,SPM- All β-lactams, 
susceptible to aztreonam and NDM-1 variable AZT resistance; IMI, NMC, GES- Weak activity against carbapenems. 
(The Pediatric Infectious Disease Journal, 2010). 
 
Enzymes in the A and D classes break down carbapenems through a serine-based 
process, while those in the B class are metallo-β-lactamases and involve zinc in the process 
(Queenan & Bush, 2007 ).  The A class carbapenemases consist of the blaKPC (KPC1-10) blaSME, 
blaGES, blaIMI, and blaNMC enzyme groups (Queenan & Bush, 2007 ). KPC carbapenemases are 
widely distributed and originate from plasmids in Klebsiella pneumoniae (Queenan & Bush, 
2007 ). Carbapenem resistance due to the presence of a class A carbapenemase was initially 
observed in 1996 from an isolate of Klebsiella pneumoniae in North Carolina  (Yigit et al., 
2001).   
In 2006, KPC-producing strains of Klebsiella pneumoniae (KPC-Kp) were connected 
with outbreaks in the United States; mostly in the Northeast and Arizona (Temkin et al., 2014). 
In one of these KPC-Kp-associated outbreaks, 24 patients in a New York City Hospital were 
affected resulting in a 33% fatality rate (Woodford et al., 2004). In 2008, KPC-Kp strains were 
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also identified in Greece, Israel, and Italy (Leavitt et al., 2007; Maltezou et al., 2009; Mezzatesta 
et al., 2011; Pournaras et al., 2009; Schwaber et al., 2011). 
Due to horizontal transfer, KPC was soon found in other types of the Enterobacteriaceae 
(Martirosov & Lodise, 2016).  Though differences exist between regions, one study found that 
KPCs exist in 4% of Escherichia coli and 10% of Klebsiella pneumoniae (Marsik and Nambiar, 
2011). KPCs are now the most widespread carbapenemase (Munoz-Price et al., 2013).   
The emergence of other carbapenemases is also well documented. The B class 
carbapenemases consist of the, blaIMP, blaVIM, blaGIM, blaSPM, and blaNDM-1. Initially discovered in 
1997 in Pseudomonas aeruginosa isolates, blaVIM was detected in Enterobacteriaceae from 
Greece in 2001  (Lauretti et al., 1999; Miriagou et al., 2003). In 2009, blaNDM-1 was reported in 
isolates from Swedish patient with a urinary tract infection (UTI) in an Indian medical center 
(Yong et al., 2009). 
The D class includes the blaOXA enzymes and are typically found in Acinetobacter 
baumannii (Bush et al., 1995; Queenan and Bush, 2007; Walther-Rasmussen and Hoiby, 2006). 
There are 120 blaOXA variants, of which over one-third hydrolyze carbapenems (Bush et al., 
1995; Queenan and Bush, 2007; Walther-Rasmussen and Hoiby, 2006).  
2.3 CRE in the Healthcare Setting 
 
According to the CDC’s 2013 Antibiotic Resistance threat report, CRE-related infections 
in the healthcare environments are increasing and considered an urgent threat (2013). The 
National Healthcare Safety Network (NHSN) collects antimicrobial susceptibility data on 
patients with catheter-associated urinary tract and blood stream infections. Data collected in 
2006-2007 showed that carbapenem resistance was observed in 0.9% of Escherichia coli 
infections and in 10.8% of  Klebsiella pneumoniae infections in hospital patients with central 
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line–associated bloodstream infections (CLABSIs) (Hidron et al., 2008). NHSN reported a rise 
in carbapenem resistance, in 2009-2010, from 10.8% to 12.8% of Klebsiella pneumoniae cultures 
associated with CLABSIs (Sievert et al., 2013).  
 At least one healthcare associated CRE infection occurred in 3.9% of short-stay acute-
care hospitals (ACH) and 17.8% of LTACHs in 2012 (Martirosov & Lodise, 2016; Vital Signs: 
Carbapenem-Resistant Enterobacteriaceae, 2013). By 2012, CRE had spread to 42 states, and the 
number of Enterobacteriaceae that were CREs had risen fourfold over a 10-year span (Vital 
Signs: Carbapenem-resistant Enterobacteriaceae, 2013). During this time frame, carbapenem 
resistance in Klebsiella pneumoniae catheter-associated UTIs (CAUTIs) rose from 10.1% to 
12.5% as well (Hidron et al., 2008; Sievert et al., 2013; Martirosov & Lodise, 2016).  Similarly, 
increasing rates of carbapenem resistance can be seen in patients with ventilator-associated 
pneumonia (VAP) ( Hidron et al., 2008; Sievert et al., 2013; Martirosov & Lodise, 2016). 
Carbapenem resistance among Klebsiella pneumoniae and Escherichia coli cases with VAP 
increased from 3.6% and 1.8%  to 11.2% and 3.5%, respectively ( Hidron et al., 2008; Sievert et 
al., 2013; Martirosov & Lodise, 2016). CRE infections occur at varying rates and are not limited 
to the hospital environment as they are found in all types of healthcare facilities; such as 
convalescent facilities and long-term acute care hospitals (LTACHs) (Martirosov & Lodise, 
2016; Hayden et al., 2014; Marquez et al., 2013). 
2.4 Risk Factors for CRE  
 
Understanding the epidemiology of the risk factors associated with CRE infections 
essential in developing effective control strategies such as early intervention in terms of 
treatment and appropriate antibiotic therapy. According to a landmark comprehensive study that 
examine the emergence of CRE across the globe, “Carbapenem-resistant Enterobacteriaceae: 
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Epidemiology and Prevention,” by Gupta et al., the most prominent risk factors for CRE 
infections are extensive time in medical facilities, exposure to medical instruments, such as 
indwelling devices, and previous exposure to antibiotics (2011). All of which were demonstrated 
in a matched-case control study conducted by Patel et al. (2008). The researchers uncovered a 
strong association between carbapenem-resistant Klebsiella pneumoniae infections and organ or 
stemcell transplants, artificial ventilation to support breathing, number of hospitalizations, 
prolonged length of stay, and previous use of carbapenems or cephalosporins (Patel et al., 2008). 
Studies that have examined the clinical characteristics of CRE cases have found that the 
severely-ill, debilitated, elderly, immunosuppressed, and those with extensive comorbidities are 
at risk for CRE infections (Gupta et al., 2011; Kim et al., 2014; Martirosov & Lodise, 2016; Patel 
et al., 2008; Perez & Van Duin, 2013; Zurawski, 2014).  Specifically, the elderly, burn victims, 
and severely-ill patients with bacteremia commonly experience the most challenging outcomes 
(Perez & Van Duin, 2013; Tumbarello et al., 2012; Zarkotou et al., 2011). Furthermore, patients 
in intensive-care units (ICU) had an increased risk of CRE-related infections compared those in 
non-critical care wards (Gupta et al., 2011; Kim et al., 2014; Martirosov & Lodise, 2016; Patel et 
al., 2008; Zurawski, 2014).  
Considering the frequency in which microbes change and adapt, many find the 
association between previous antibiotic therapy with carbapenems a primary cause of rising CRE 
rates. However, results from several studies show that it is, actually, the cumulative treatment of 
antibiotics rather than treatment of a single antibiotic class, that fuels CRE rates (Gallagher et al., 
2014; Marchaim et al., 2012; Patel et al., 2011). This response to a consistent influx of and 
collective exposure to antimicrobials occurs by disturbing the colonization of the “good 
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bacteria,” rendering patients more susceptible to resistant pathogens like CRE (Patel et al., 
2011).  
 2.5 The Role of Long-Term Care Facilities in the Spread of CRE 
 
 The association between  LTCFs and the spread of CREs has been highlighted in a 
number of studies and evidence suggests LTCFs may play a central role among the list of risk 
factors responsible for the proliferation of CREs (Perez et al., 2010; Perez & Van Duin, 2013). 
Additionally, researchers determined from a retrospective observational study, that over 50% of 
CRE-linked infections were transferred from an LTCF (Perez et al., 2010). Data collected from 
an investigation on carbapenem-resistant Acinetobacter baumannii and Klebsiella  pneumoniae 
in a group of medical facilities showed 75% of carbapenem-resistant Klebsiella  pneumoniae 
came from LTCFs (Perez & Van Duin, 2013). One study that focused on movement of patients 
with carbapenem-resistant associated bloodstream infections between hospitals and LTCFs 
determined that of the 42% that survived their index admission, just 32% were discharged, and 
overall, readmissions occurred frequently (Perez & Van Duin, 2013; Neuner et al., 2011). 
Transfers from LTCFs or another medical facility is linked to carbapenem-resistance in patients 
colonized or infected with Enterbacteriaceae. Though researchers recognize LTCFs to be at the 
forefront of the emergence and transmission of CREs, it is important to note that location of care 
can and often overlaps with other risk factors.  
2.6 Rationale for Case Definition Change 
Carbapenem resistance within the Enterobacteriaceae family is uniquely challenging. 
There are over 70 Enterobacteriaceae classes with a variety of mechanisms that can create 
carbapenem resistance (CDC, 2015). Irrespective of the mechanism behind the carbapenem 
resistance, all CRE are typically multidrug-resistant pathogens that warrant immediate attention 
in healthcare settings to prevent and control transmission. However, carbapenemase-producing  
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CREs (CP-CRE) are considered to be the prime cause for the proliferation of CRE in the United 
States and thus have been the focus for aggressive prevention strategies (CDC, 2015; Chea et al., 
2015). Distinguishing CP-CRE from non-CP-CRE is the most reliable approach to thwarting the 
spread of CRE (CDC, 2015; Chea et al., 2015). Mechanism testing, however does not serve as a 
guide in making therapeutic decisions and it is not commonly performed in clinical laboratories 
across the US (CDC, 2015; Chea et al., 2015). In the absence of mechanism testing, phenotypic 
definitions, regarding a pathogens antibiotic susceptibility pattern, are the principal method for 
identifying CP-CRE (CDC, 2015). It is important to note that no phenotypic definition is 100% 
accurate in differentiating CP-CRE from non-CP-CRE (CDC, 2015; Chea et al., 2015). 
The previous phenotypic CRE surveillance definition (nonsusceptibility to doripenem, 
meropenem, or imipenem AND resistant to all third-generation cephalosporins; ceftriaxone, 
cefotaxime, and ceftazidime) was intended to capture more CP-CRE (Chea et al., 2015). 
However, there were several issues; automated testing instruments were not testing low enough, 
the CDC CRE case definition did not align with state-reportable definitions, and low sensitivity 
for capturing CP-CRE (CDC, 2015; Chea et al., 2015). The challenge was due to the sheer 
number of antibiotics involved and the different standards for specific antibiotics (i.e. 
nonsusceptibility for carbapenems and resistance for cephalosporins). Moreover, ertapenem, 
another carbapenem, was initially excluded in the definition because of apprehension regarding 
its low cutoff for nonsusceptibility ( ≥1 mcg/ml) (CDC, 2015; Chea et al., 2015).  
In time, concerns over whether the original definition missed CP-CRE prompted more 
investigation on its performance. Eventually, the CDC began identifying CRE that contained the 
KPC gene (blaKPC) and showed resistance to ertapenem but were susceptible other carbapenems  
(Humphries & McKinnell, 2016). The results from a validation study conducted by the CDC 
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indicated that some of KPC-producing Klebsiella species might be overlooked by not including 
ertapenem in the definition (Arnold et al., 2011). Also, some clinical laboratories only tested 
ertapenem, meaning CRE would not be identified with the previous definition (CDC, 2015).  
Lastly, CRE producing OXA-48 carbapenemases may not be resistant to third-generation 
cephalosporins and thus would not be identified using the former definition (CDC, 2015). 
Therefore, to make testing more simple and reliable, considerable effort was put into creating a 
more suitable set of criteria for identifying CREs (CDC, 2015; Chea et al., 2015). By January 
2016, the CDC changed its CRE definition to resistance to imipenem, meropenem, doripenem, or 
ertapenem  (see Table 2) (CDC, 2015; Chea et al., 2015). 
Table 2: CRE Case Definitions 
2011-2015 
Category Species Carbapenem susceptibility phenotype 
Carbapenem-
nonsusceptible 
Enterobacteriaceae 
Escherichia coli 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Enterobacter cloacae 
Enterobacter 
aerogenes 
 Intermediate or resistant to:     
         Imipenem (MIC ≥2),  
         Meropenem (MIC ≥2),  
         or Doripenem (MIC ≥2)  
AND resistant to:  
        Ceftazidime (MIC ≥16),  
        Ceftriaxone (MIC ≥4),  
        and Cefotaxime (MIC ≥4 
2016 
Carbapenem-
nonsusceptible 
Enterobacteriaceae 
Escherichia coli 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Enterobacter cloacae 
Enterobacter 
aerogenes 
Resistant to:     
        Imipenem (MIC ≥4),  
        Meropenem (MIC ≥4),  
        Doripenem (MIC ≥4), 
        or Ertapenem (MIC ≥2)   
 
Including ertapenem in the new definition increased the likelihood of capturing more 
non-CP-CRE than that of the former definition (CDC, 2015). Resistance to all third-generation 
cephalosporins was omitted from the new CDC CRE definition for several reasons: to make the 
definition easier to implement; to adequately address the rise in OXA-48 producing CRE, as they 
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may not show resistance to this group of antibiotics and; there was a sufficient amount of 
evidence that the inclusion of cephalosporins requirement did not significantly increase 
sensitivity and specificity for CP-CRE (CDC, 2015). 
         A standardized, reliable phenotypic surveillance definition for CRE is vital for prevention. 
Accurate diagnoses of CREs, especially those of greatest epidemiological interest such as CP-
CRE, aids in prevention efforts. A standardized surveillance definition is also essential for 
obtaining national burden estimates as it ensures consistent reporting from laboratories across the 
country (CDC, 2015; Chea et al., 2015). 
3. METHODS AND PROCEDURES 
 
3.1 Surveillance Population 
 
    The Multi-site Gram Negative Surveillance Initiative (MuGSI), as part of the Center for 
Disease Control (CDC)’s Emerging Infections Program (EIP), conducts active, population-based 
laboratory surveillance for carbapenem-resistant gram-negative bacteria.   
Figure 1: Georgia Emerging Infections Program Surveillance Area 
                                  
https://dph.georgia.gov/sites/dph.georgia.gov/files/site_page/Monica%20Farley.pdf 
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Georgia is one of eight EIP sites nationwide that conducts surveillance for carbapenem-
resistant Enterobacteriaceae (CRE).  The surveillance catchment area for the Georgia site is the 
Health District 3 (HD3), which contains eight counties in the metropolitan Atlanta area: Cobb, 
Clayton, Dekalb, Douglas, Gwinnett, Fulton, Newton, and Rockdale (Figure 1).  Therefore, this 
study includes confirmed CRE cases in HD3.                                   
      3.2 Case Definition 
In order to be considered a case, the specimen must be, initially, collected from urine or 
normally sterile body site (blood, bone, pleural fluid, etc.). It must meet the phenotypic case 
definition, and the patient must be a resident of the surveillance area (HD3). The phenotypic case 
definition from 2011-2015 (study period 1) required that the isolate be nonsusceptible to at least 
one of the following carbapenems: doripenem, meropenem, or imipenem AND resistant to the 
following third-generation cephalosporins; ceftriaxone, cefotaxime, and ceftazidime. In 2016 
(study period 2), the phenotypic case definition was changed to resistant to imipenem, 
meropenem, doripenem, or ertapenem. If a new culture meeting the case definition is collected 
more than 30 days after the patient’s initial positive culture, it will be reported as a new incident 
case.  If a positive culture is collected within 30 days after the initial positive culture than it will 
be considered persistent disease and recurrent case.  
Susceptibility results were closely reviewed to verify resistance. Minimum Inhibitory 
Concentrations (MIC) were established using the Clinical and Laboratory Standards Institute 
(CLSI), Seventieth Information Supplement (M100-S26) (Outreach Working Group of the CLSI 
Subcommittee on Antimicrobial Susceptibility Testing, 2016) 
3.3 Data Collection 
Cases of CRE are identified through querying of automated testing instruments at clinical 
laboratories serving residents of the surveillance population (Reno et al., 2014). Epidemiological 
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data included: are captured through retrospective medical record review for all incident cases by 
trained EIP staff members. Epidemiological data extracted include: demographic data, 
underlying conditions, location of culture collection, types of infection associated with the 
positive culture, outcome, susceptibility testing results, risk factors/healthcare exposures 
(including invasive devices, residence in long-term care facilities, previous 
hospitalizations/surgeries, travel).    
3.4 Data Analysis 
 
     The following variables were included in this analysis: age-group, year of incident and 
corresponding study period, gender, race, ethnicity, CRE diagnosis, origin of incident (whether a 
case was nosocomial, transferred from an LTCF, or other), and outcome (whether a patient 
survived or died). Variables pertaining to healthcare exposures were also examined: residence in 
a long-term care facility within year before date of initial culture, culture collection at least 3 
calendar days after hospital admission, hospitalization in ICU in the 7 days prior or after to their 
initial culture, hospitalization or surgery in the previous year before date of initial culture, and 
admission to a LTACH wihin year before initial culture date. Other risk factors for CRE 
infection or other epidemiologically significant information were chronic dialysis within year 
before date of initial culture, culture source (urine or invasive, from normally sterile site), 
presence of indwelling devices (i.e. urinary catheter, central vascular catheter, tracheostomy, etc) 
in place on the day of culture or at any time in the 2 calendar days prior to initial culture, and 
comorbidities (diabetes, immunocompromised, HIV, etc.) 
           Data were analyzed using SAS software (v. 9.4). Cumulative incidence rates were 
calculated using Census Bureau data from 2011-2016 per 100,000 population ( Data Access and 
Dissemination Systems (DADS), 2018). Univariable demographic and risk factor comparisons 
were done between patients with positive urine or sterile site cultures. Chi2 or Fisher’s exact tests 
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were calucated for categorical variables. P-values <0.05 were considered significant. Univariable 
logistic regression was done with each risk factor as the sole predictor of outcomes of invasive 
infection by study period. Multivariable modeling was conducted using invasive infection as the 
outcome of interest and the new case definition as the primary exposure. Backward, forward, 
stepwise, and manual selection techniques utilized to identify the best-fitting model at p<0.05. 
Variables were used in the final multivariable model to control for each covariate. The model 
included culture source type as the dichotomous outcome variable and predictors (old and new 
case definition, hospitalization three days or more of initial culture, hospitalization in the year 
prior to the initial culture, presence of a urinary catheter, central venous catheter, or other 
indwelling devices.  
4.  RESULTS 
    4.1  Descriptive Analysis 
   A total of 1,144 confirmed cases of CRE infections were reported from 2011-2016 in 
HD3. In study period 1, the population in the HD3 increased from 3,753,452 (38% of the state 
population) to 3,991,607 (39% of the state population).  The first study period consists of 757 
CRE cases, of which 149 (19.7%) were invasive infections. The second study period had 387 
CRE cases, with 31 (2.7%) that were invasive infection. In both periods, the number of non-
invasive CRE infections greatly exceeded the number of invasive infections (blood and all other 
sterile sites) (Figures 2-3) (Tables 3-4).  
From 2011 to 2016, 8.5% (97/1144) of all CRE infections resulted in death. We 
measured outcome at 30 days for non-hospitalized patients or at discharge from acute care 
hospital for hospitalized patients. There were more deaths in the first period than in the second, 
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as study period one had more years; 72/757 vs. 25/387 respectively (Table 3-4). During study 
period 1, however the mortality rate for invasive CRE infections increased from 3.8 to 6.7, but-  
Table 3: Study Period 1 Patient Characteristics by Culture Source 
Participant Characteristics  INVASIVE 
149 (19.7) 
NON-INVASIVE 
608 (80.3) 
Overall  
N=757 
 
p-value 
**Age Group 
0-9 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
90+ 
 
 
3 (13.6) 
0  
14 (40.0) 
16 (42.1)  
14 (24.1) 
28 (23.9)  
37 (21.3) 
16 (12.6)  
11 (11.9) 
2 (6.9) 
 
19 (86.4) 
3 (100.0)  
21 (60.0) 
22 (57.9)  
44 (75.9) 
89 (76.1)  
137 (78.8) 
111 (87.4)  
81 (88.0) 
28 (93.3) 
 
22 
3 
35 
38 
58 
117 
174 
127 
92 
30 
 
<.0001 
**Gender 
Female   
Male 
 
76 (17.9)  
73 (22.1) 
 
 
349 (82.1)  
258 (77.9)  
 
 
425 
331 
 
 
.3176 
**Race 
American Indian 
Asian 
Black 
White 
 
**Ethnicity 
Hispanic or Latino 
Non-Hispanic or Latino 
 
 
0  
4 (44.4) 
95 (21.9)  
40 (16.5) 
 
 
6 (27.3)  
88 (19.5) 
 
1 (100.0) 
5 (55.6) 
339 (78.1) 
203 (83.5) 
 
                 
                16 (72.7)  
363 (80.5) 
 
1 
9 
434 
243 
 
 
22 
451 
 
 
0.0931 
 
 
 
 
 
0.6610 
**Location of Culture  
ER 
ICU 
LTACH 
LTCF 
OBS 
OPCL 
OPSUR 
OR 
OTHIP 
OTHOP 
RAD 
 
 
37 (19.1)  
34 (38.6) 
7 (20.6)  
6 (3.3)  
0 
2 (4.4)  
0 
4 (66.7)  
53 (28.8) 
3 (21.4)  
2 (100.0)  
 
 
157 ( 80.9)  
54 (61.4) 
27 (79.4)  
175 (96.7)  
3 (100.0) 
43 (95.6)  
1 (100.0) 
2 (33.3)  
131 (71.2) 
11 (78.6)  
0  
 
 
194 
88 
34 
181 
3 
45 
1 
6 
184 
14 
2 
 
 
<.0001 
**Outcome  
Died 
Survived  
 
 
26 (36.1) 
123 (18.7)  
 
 
 
46 (63.9) 
534 (81.3)  
 
 
 
72  
657  
 
 
<.0001 
**Missing: Age group(61). Variables: Origin of Culture indicates whether a case was nosocomial, transferred from a longterm care facility (LTCF), or other 
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient character and culture source pre-case definition (2011-2015) 
Origin of Culture variable abbreviations: CU=ICU, OR=Surgery/OR,  RAD=Radiology, OTHIP=Other Hospital IP Unit,  ER=Emergency Room,  OPCL=Outpatient Clinic/Doctor's office 
OPSUR=Outpatient Surgery,  OTHOP=Other Outpatient, DIAL=Dialysis Center, OTHER = Other, OBS=Observational Unit/Clinical Decision Unit, LTCF=LTCF, LTACH=LTACH, 
AUTO=Autopsy, and UNK=Unknown. 
 
peaked at 9.8 in 2014 (Figure 3). During the same period, the mortality rate for non-invasive 
infections increased from 1.3 to 2.5 per 100,000 but peaked at 6.4 in 2013. In the second study 
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 Table 4: Study Period 2 Patient Characteristics by Culture Source 
Participant Characteristics  Invasive 
31 (8.1) 
Non-Invasive 
356 (91.9) 
Overall 
N=387 
 
p-value 
**Age Group 
0-9 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
90+ 
 
 
0 
  1 (25.0)  
1 (5.9) 
2 (6.9)  
2 (7.4) 
4 (11.4)  
7 (8.4) 
7 (8.2)  
2 (3.9) 
2 (9.5) 
 
7 (100.0) 
3 (75.0)  
16 (94.1) 
27(93.1)  
25 (92.6) 
31 (88.6)  
76 (91.6) 
78 (91.8)  
49 (96.1) 
19 (90.5) 
 
7 
4 
17 
29 
27 
35 
83 
85 
51 
21 
 
<.8959 
**Gender 
Female   
Male 
 
 
10 (4.7) 
21 (12.3) 
 
 
205 (95.4)  
150 (87.7) 
 
 
215 
171 
 
 
0.0222 
**Race 
American Indian 
Asian 
Black 
White 
 
**Ethnicity 
Hispanic or Latino 
Non-Hispanic or Latino 
 
 
 
 
0  
3 (21.4) 
20 (11.8)  
7 (4.6) 
 
 
1 (7.7)  
30 (9.0) 
 
0 
11 (78.6) 
150 (88.2) 
145 (95.4) 
 
 
12 (92.3)  
305 (91.0) 
 
0 
14 
170 
152 
 
 
13 
335 
 
 
0.0094 
 
 
 
 
 
0.1643 
**Location of Culture  
ER 
ICU 
LTACH 
LTCF 
OBS 
OPCL 
OPSUR 
OR 
OTHIP 
OTHOP 
OTH 
 
 
3 (3.1) 
9 (36.0) 
4 (18.2) 
0 
0 
1 (1.4) 
0 
4 (80.0) 
10 (12.9) 
0 
0 
 
93 (96.9) 
16 (64.0) 
18 (81.8) 
80 (100.0) 
1 (100.0) 
72 (98.6) 
1 (100.0) 
1 (20.0) 
67 (87.0) 
1 (100.0) 
3 (100.0) 
 
96 
25 
22 
80 
1 
73 
1 
5 
77 
1 
3 
 
<.0001 
**Outcome  
Died 
Survived  
 
 
9 (36.0) 
22 (6.6)  
 
 
16 (64.0) 
311 (93.4)  
 
 
25 
333 
 
 
<.0001 
**Missing: Age group(28) & Outcome (1). Variables: Origin of Culture indicates whether a case was nosocomial, transferred from a longterm care facility (LTCF), or other  
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient character and culture source for post case definition change (2016) 
Origin of Culture variable abbreviations: CU=ICU, OR=Surgery/OR,  RAD=Radiology, OTHIP=Other Hospital IP Unit,  ER=Emergency Room,  OPCL=Outpatient Clinic/Doctor's office 
OPSUR=Outpatient Surgery,  OTHOP=Other Outpatient, DIAL=Dialysis Center, OTHER = Other, OBS=Observational Unit/Clinical Decision Unit, LTCF=LTCF, LTACH=LTACH, 
AUTO=Autopsy, and UNK=Unknown. 
 
Much of the disease burden of all CRE infections, in both study periods, was between 
ages 60-69; 22.9% and 21.5% respectively (Tables 3-4). All subjects in the dataset were 
stratified into ten age groups. 
period, the mortality rate for invasive infections increased to 4.5. and to 2.5 per 100,000 for 
non-invasive infection (Figure 3).  
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Females accounted for the majority of CRE infections in both periods; 56.1% and 55.6% 
respectfully (Tables 3-4). Blacks had the greatest number of CRE infections, invasive and non-
invasive, before and after the case definition change; 57.3%  (170/387) and 43.9% (434/757) 
(Tables 3-4). In the first study period, most cultures were originally collected from the 
emergency room-ER, 194 (25.6%), an LTCF 181 (23.9%), other hospital in-patient unit-OTHIP 
184 (24.3%), or ICU 88 (11.6%)  (Table 3). Similarly, most cultures in the second study period 
were collected in the ER 96 (24.8%),  LTCF 80 (100.00%), OTHIP 77 (19.9%), or outpatient 
clinic/doctor's office-OPCL 73 (18.9%)  (Table 4).  
CRE incidence rates for both invasive and non-invasive infections decreased during study 
period 1 from 9.4 to 2.5 per 100,000 (Figure 2). These rates continued to decrease in study 
period 2 to 1.6 per 100, 000, following the CRE case definition change. 
  Figure 2: Crude Annual Cumulative Incidence of CRE Cases in HD3 
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Figure 3: Crude Annual Mortality Rate for CRE Deaths in HD3 
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4.2 CRE Organism Distribution 
The distribution of CREs prior to the case definition change shows that Klebsiella 
pneumoniae infections accounted for 64% (488) of all CRE infections; 14.8% (112) of which 
were invasive (Figure 4). Escherichia coli CRE infections 18.8% (114) were the second most 
common in this sample, with 8.7% (13) (Figure 4). Distributions for the remaining CRE 
infections were as were: Enterobacter aerogenes 5.4% (8), Enterobacter cloacae 9.4% (14), and 
Klebsiella oxytoca 2% (0.3).  Most these infections were non-invasive as well. In study period 1, 
Escherichia coli CRE infections, 34.9% (135), were the second most present in this sample, with 
16.1% (5) (Figure 5). 
Figure 5: Organism Distribution  
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Enterobacter aerogenes-15% (3.9), Enterobacter cloacae-22.5% (87), and Klebsiella oxytoca 
2.1% (8) (Figure 5). In both study periods, most CRE infections were non-invasive. 
4.3 Risk Factors  
 For study period 1, the relationship between eleven risk factors for CRE infections and 
invasive infections was assessed (see Table 5). Of these risk factors, having chronic dialysis and 
being hospitalized for three or more days during culture collection showed the greatest 
percentages. Of those with chronic dialysis, 39.6% (36/91) were invasive. For those hospitalized 
for three or more days at the time of culture collection, 34.3% (50/146) were invasive.  
Percentages of invasive infections in patients with the following risk factors were similar; central 
venous catheters 33.1% (83/251 cases), indwelling devices 27.5% (83/302), and surgery in the 
year prior to culture collection 27.1% (51/188). All five risk factors were statistically significant 
with p-values <.0001. 
Table 5: Study Period 1 - Risk Factors for Invasive Infection 
Risk Factors Invasive 
149 (19.7) 
Non-Invasive 
608 (80.3) 
Overall 
N=757 
pvalue 
ICU prior to positive culture 32 (34.0) 62 (66.0) 94  <.0001 
Hospitalized for ≥3 days 50 (34.2) 96 (65.8) 146  <.0001 
Hospitalized in the last year 97 (18.7) 423 (81.3) 520  .0049 
Surgery within the last year 51 (27.1) 137 (72.9) 188  <.0001 
Urinary catheter present 69 (17.6) 323 (82.4) 392  .2492 
Central venous catheter 83 (33.1) 168 (66.9) 251  <.0001 
Other indwelling device 83 (27.5) 219 (72.5) 302  <.0001 
In an LTCF in the year prior 46 (11.6) 350 (88.4) 396  .0004 
In an LTACH in the year prior 20 (24.4) 62 (75.6) 82  .0309 
Chronic dialysis 36 (39.6) 55 (60.4) 91  <.0001 
Immunocompromised 84 (18.5) 370 (81.5) 454  .0289 
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and 
culture source for pre-CRE case definition change (2011-2015). 
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital. 
Variable information: data for variables  regarding culture collection “after hospitalized for ≥ 3 days” or “ in an LTACH in the 
previous year” was largely incomplete; Immunocompromised is a composite variable comprised of diabetes, chronic renal failure, 
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS, 
hematologic malignancy. 
 
Similar percentages were reported in the second study period. The top five most notable 
predictors of invasive CRE infections were stay in the ICU, hospitalization for three or more 
days at the time of culture collection, the presence of a central venous catheter, chronic dialysis, 
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and stay in LTACH in the year prior to original collection (see Table 6). Of which, stay in the 
ICU (34) and chronic dialysis (29) presented the highest percentages for invasive infections; 
41.2% (14/34)  and 31.1% (9/29) respectively. Percentages of the patients with the other 
riskfactors in this subset, that had invasive infections were hospitalization for three or more days 
at the time of culture collection 29.5% (18/61), central venous catheters 25.3% (23/91 cases), and 
stay in LTACH in the year prior to original culture collection 21.9% (9/41). All five risk factors 
were statistically significant with p-values no greater than .0016. 
Table 6: Study Period 2 - Risk Factors for Invasive Infection 
Risk Factors Invasive  
31 (8.1) 
Non-Invasive 
356 (91.9) 
Overall  
N=387 
pvalue 
ICU prior to positive culture 14 (41.2) 20 (58.8) 34 <.0001 
Hospitalized for ≥3 days 18 (24.5) 43 (75.5) 61 <.0001 
Hospitalized in the last year 23 (10.9) 188 (89.1) 211 .1076 
Surgery within the last year 13 (12.6) 90 (87.4) 103 .1084 
Urinary catheter present 22 (12.2) 158 (87.8) 180 .0259 
Central venous catheter 23 (25.3) 68 (74.7) 91 <.0001 
Other indwelling device 21 (21.0) 79 (79.0) 100 <.0001 
In an LTCF in the year prior 10 (8.3) 111 (91.7) 121 .8071 
In an LTACH in the year prior 9 (22.0) 32 (78.0) 41 .0016 
Chronic dialysis 9 (31.1) 20 (68.9) 29 <.0001 
Immunocompromised 21 (10.3) 183 (89.7) 204 .2683 
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between 
patient risk factors and culture source for pre-CRE case definition change (2016). 
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital. 
Variable information: Immunocompromised is a composite variable comprised of diabetes, chronic renal failure, 
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver 
failure, AIDS, hematologic malignancy. 
 
 
 
 
In both study periods, having a central venous catheter, hospitalization for three or more 
days at the time of culture collection and chronic dialysis are among the top five most prevalent 
risk factors for the invasive CRE infections. However, not all risk factors being study periods are 
statistically significant. For example though statistically significant in as a prevalent risk factor 
for invasive CRE infections post case definition change, the presence of a urinary catheter was 
not statistically signicant pre-case definition change (p=.2492). On the other hand, after the case 
definition change, unlike those in study period one, some risk factors were not statistically 
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significant;  hospitalization in the last year (p=.1076), surgery within the last year (p=.1084),  
being immunocompromised (p=.2683), and stay in an LTCF in the previous year (p=.8071).  
4.4 Univariable Analysis 
 
A univariable logistic regression analysis was conducted to gauge the strength of the 
association between the eleven risk factors for CRE infections and invasive infection with both 
study periods.  
Table 7: Study Period 1 - Risk Factors for Invasive Infection 
Risk Factors *Crude OR 95% CI Adjusted OR         95% CI 
Central venous catheter 6.8 4.7-9.8 *5.9 3.9-8.9 
Other indwelling device 4.6 3.2-6.6 *4.0 2.7-6.1 
Immunocompromised 1.6 1.1-2.3 *1.6 1.1-2.4 
Surgery within the last year 2.3 1.6-3.3 *2.6 1.7-3.9 
Hospitalized in the last year 2.1 1.4-3.1 *1.9 1.2-3.1 
Hospitalized for ≥3 days 4.7 3.-6.8 *3.9 2.6-5.9 
ICU prior to positive culture 4.4 2.9-6.6 *3.1 1.9-4.5 
In an LTCF in the year prior 0.6 0.5-0.9 *0.5 0.3-0.7 
In an LTACH in the year prior 2.2 1.4-3.4 *1.8 1.1-3.1 
Urinary catheter present 1.5 1.1-2.1 1.3 0.8-1.9 
Chronic dialysis 4.9 3.3-7.5 *4.1 2.7-7.1 
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and 
culture source for pre-CRE case definition change (2011-2015). *denotes statistical significance. 
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital. 
Variable information: data for variables  regarding culture collection “after hospitalized for ≥ 3 days” or “ in an LTACH in the 
previous year” was largely incomplete; Immunocompromised is a composite variable comprised of diabetes, chronic renal failure, 
solid tumor malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS, 
hematologic malignancy. 
 
 
Table 8: Study Period 2 - Risk Factors for Invasive Infection 
Risk Factors *Crude OR 95% CI Adjusted OR         95%CI 
Central venous catheter 6.8 4.7-9.8 *8.8 4.01-18.9 
Other indwelling device 4.6 3.2-6.6 *5.6 2.7-11.7 
Immunocompromised 1.6 1.1-2.3 1.5 0.7-3.1 
Surgery within the last year 2.3 1.6-3.3 1.8 0.9-3.8 
Hospitalized in the last year 2.1 1.4-3.1 1.8 0.9-3.9 
Hospitalized for ≥3 days 4.7 3.3-6.8 *8.1 3.9-17.1 
ICU prior to positive culture 4.4 2.9-6.6 *11.2 4.9-25.6 
In an LTCF in the year prior 0.6 0.5-0.9 0.91 0.4-1.9 
In an LTACH in the year prior 2.2 1.4-3.4 *3.6 1.6-8.4 
Urinary catheter present 1.5 1.1-2.1 *2.3 1.1-4.7 
Chronic dialysis 4.9 3.3-7.5 *5.9 2.5-14.5 
Chi-square was used to calculate p-values using 95 % confidence interval (CI) for the association between patient risk factors and 
culture source for pre-CRE case definition change (2016). * denotes statistical significance. 
Abbreviation: ICU-Intensive Care Unit and LTACH-longterm acute care hospital. 
Variable information: Immunocompromised is a composite variable comprised diabetes, chronic renal failure, solid tumor 
malignancy, connective tissue disease, solid organ transplant metastatic solid tumor, cirrhosis/liver failure, AIDS, hematologic 
malignancy. 
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            In the study period 1, the presence of a central venous catheter was strongly associated 
with invasive CRE infections (OR 5.9, 95% CI 1.4 - 4.3). Thus, cases involving a central venous 
catheter in this study were 5.9 times more likely to have an invasive infection than those without 
a central venous catheter. There were strong associations found between invasive CRE infection 
and other risk factors as well; chronic dialysis (4.4, 95% CI 2.7-7.1) and other indwelling devices 
(4.0, 95% CI 2.7-6.1).  
In the study period 2, staying in an ICU prior to having a positive culture had the 
strongest association with invasive CRE infections (OR 11.2, 95% CI 4.91-25.6). Patients with 
ICU stay in prior seven days are 11.2 times more likely to have an invasive CRE culture than 
patients that did not have an ICU stay in previous seven days.  
Along with ICU status prior to having a positive culture, markedly strong associations 
were found invasive CRE infections and the following risk factors: central venous catheter (OR 
8.8 , 95% CI 4.1-18.9), or other indwelling devices (OR 5.6, 95% CI 2.7-11.7), and 
hospitalization for three of more days (OR 8.1, 95% CI 3.9-17.1)  
4.5 Multivariable Analysis 
 
   A multivariable logistic regression model was constructed to test the following 
hypothesis: If the current CDC CRE surveillance definition was designed to be more simple and 
sensitive, surveillance efforts in Atlanta should have an impact on patient profiles. This analysis 
was performed using invasive infection as the outcome of interest and study period (pre and post 
case definition change)  as the predictor of interest. Manual, backward, forward, stepwise 
selection methods were employed to ascertain the best-fitting model (Figure 6).  
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Figure 6: Final Multivariable Logistic Regression Model of the Association between New 
Case Definition and Invasive CRE Infections  
 
Logit Invasive AND Non Invasive CRE Infections = β 0 +  β 1(New Case Definition) +
 β2(Hospitalized >= 3 days) +  β3(Hospitalized in the year prior) +
β4(Central venous catheter present) +  β5(Other indwelling device) + β6(LTCF )+ 
β7(Chronic Dialysis) 
 
Logit 𝐼𝑛𝑣𝑎𝑠𝑖𝑣𝑒 𝐶𝑅𝐸 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠 (𝑁𝑒𝑤 𝐶𝑎𝑠𝑒 𝐷𝑒𝑓𝑖𝑛𝑖𝑡𝑖𝑜𝑛) = β 0 +  β 1(1) +  β2(1) +  β3(1) + β4(1) +  β5(1) +  β6(1) + β7(1)
Logit 𝐼𝑛𝑣𝑎𝑠𝑖𝑣𝑒 𝐶𝑅𝐸 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠 (𝑂𝑙𝑑 𝐶𝑎𝑠𝑒 𝐷𝑒𝑓𝑖𝑛𝑖𝑡𝑖𝑜𝑛  ) = β 0 +  β 1(0) +  β2(1) +  β3(1) + β4(1) +  β5(1) +  β6(1) + β7(1)
 
                                   *These covariates were pulled from literature and exhibit statistically significant bivariate associations.  
                                     The final model was derived from stepwise selection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In multivariable analysis new case definition (OR 0.6, 95% CI 0.4-0.9), culture ≥ 3 days 
(OR 8.1, 95% CI 3.9-17.1), hospitalization in ≤1 year (OR 1.8, 95% CI 0.9-3.9), central venous 
catheter (OR 8.8, 95% CI 4.08-18.9), other indwelling device (OR 5.7, 95% CI 2.7-11.7), 
chronic dialysis (OR 5.9, 95% CI 2.5-14.5), and LTCF (OR 0.9, 95% 0.4-1.9) predicted invasive 
CRE infection (Table 9). 
Table 9: Final Multivariable Model for the Association 
between New Case Definition and Invasive CRE Infection 
Covariates Crude OR Adjusted OR 
Hospitalized >=3 days 
     No 
     Yes 
 
1.00 
*4.7 (3.3-6.8) 
 
1.00 
*8.11(3.9-17.1) 
Hospitalized in the prior year 
     No 
     Yes 
 
1.00 
*2.1 (1.4-3.1) 
 
1.00 
1.84 (0.9-3.9) 
Central Venous Catheter present 
     No 
     Yes 
 
1.00 
*6.8 (4.7-9.8) 
 
 
1.00 
*8.76 (4.1-18.9) 
Other indwelling device 
     No 
    Yes 
 
1.00 
*4.6 (3.2-6.6) 
 
1.00 
*5.68 (2.7-11.7) 
 
Chronic Dialysis 
    No 
    Yes 
 
LTCF 
     No 
     Yes 
 
1.00 
*4.9 (3.3-7.5) 
 
 
1.00 
*0.6 (0.5-0.9) 
 
 
1.00 
*5.99 (2.5-14.5) 
 
 
1.00 
0.91 (0.4-1.9) 
Case Definition 
     Old 
     New 
 
1.00 
*0.5 (0.3-0.8) 
 
1.00 
*0.61 (0.4-0.9) 
* Indicates statistical significance.Multivariable logistic regression; adjusted model included the following 
covariates:Study Period Case Definition, Hospitalized >=3 days, Hospitalized in the year prior, central venous 
catheter present, other indwelling device, chronic dialysis, and stay in longterm care facility. Old case definition was 
reference group. * Indicates statistical significance. All ORs were statistically significant. 
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5. DISCUSSION AND CONCLUSION 
Regarding culture source, the final results in the analysis show how the new case 
definition change may have impacted the patient population under surveillance. For instance, 
2016 had the highest number non-invasive infections of all previous years in the study. The 
heaviest burden of disease remains among CRE patients 60-69 years of age in both study 
periods. Further, although most cultures were originally collected in the ER, LTCF, and OTHIP 
for both study periods, a more substantial number of cultures were collected in OPCLs in the 
first study period and a greater number of cultures were collected in ICUs in the second study 
period (Table 3-4).  
The univariable analysis revealed presence of a central venous catheter to have the 
strongest association with invasive CRE infections (OR 5.9, 95% CI 1.4 - 4.3). In the second 
study period, staying in an ICU prior to having a positive culture had the strongest association 
with invasive CRE infections (OR 11.2, 95% CI 4.9-25.6).  
 Though slightly, the new case definition is predictive of invasive infections. Controling 
for notable risk factors, cases of CRE infections in the metropolitan Atlanta area following the 
new CRE case definition change had a 40% lower odds of invasive infections than that of the 
previous case definition. Ultimately, considering the limitations in this analysis, it is uncertain 
whether the new case definition directly led to this shift. Perhaps this impact is indicative of a 
more effective case definition as it was intended for the new case definition to be more specific 
and sensitive in detecting CRE infections. Nevertheless, this association warrants further 
investigation as few studies have examined the impact of the new CRE case definition on CRE 
surveillance efforts. The ability to more accurately capture invasive CRE infections is paramount 
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in controlling the spread of CRE, as invasive infections are far more severe than non-invasive 
infections.   
3.5 Limitations 
          There are some limitations restricting the results of this study. The new case definition was 
also designed to capture more carbapenemase-producing CREs, however it is unclear if this goal 
was met regarding this sample as the presence of a carbapenemase was unknown for the majority 
of cases. Thus, the MuGSI surveillance personnel, are unable to evaluate sensitivity and 
specificity for detecting carbapenemase. The surveillance population is not representative of 
entire state or country, which produces low generalizability of results. Susceptibility testing 
capabilities may differ across laboratories and some testing instruments may not test low enough 
to detect non-susceptibility during 2011-2015.  Lastly, not all reference labs serving the 
catchment area participated therefore CRE burden may be underestimated.   
5.2 Recommendations and Future Studies 
         Moving forward, the Georgia EIP MuGSI surveillance efforts should differentiate CP-
CREs from all other CREs in future samples, as this was a key goal for employing the new 
definition. Including and examining these elements, would help create a clearer picture of how 
the new case definition is being employed across the HD3 catchment area.  
 In short, the initial CDC CRE case definition, with its limited carbapenem criteria and 
poor ability to detect some CP-CREs, proved to be inadequate in identifying CREs (Chea et al., 
2015). Case criteria that include non-susceptibility to any one of the four carbapenems is 
certainly simpler and capable of missing carbapenemase-producing strains, but with potential for 
capturing more non-carbapenemase producing CRE (Humphries & McKinnell, 2016). Thus, 
readjustments to the CRE case definition in the future may be necessary. All pathogens that are 
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resistant to a carbapenem represent isolates with high levels of drug resistance and warrant 
utilization of prevention and control strategies such as contact precautions to mitigate 
transmission. Medical facilities in Atlanta and beyond, could opt to designate more direct 
interventions, such as screening patient contacts and patient cohorting, for cases with cultures 
that meet these new criteria (Chea et al., 2015).  Medical facilities desiring to curtail the work 
and cost that comes with more aggressive prevention and control strategies could conduct 
resistance-mechanism testing on cultures meeting the criteria outlined in the new case definition 
and reserve interventions for the isolates that show the production of carbapenemases (Chea et 
al., 2015). 
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